Apogee Therapeutics Inc (APGE)

$38.14 -0.43 (-1.11%)
Market Cap 1.78B
Revenue (ttm) 0.00
Net Income (ttm) -182.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 953,900
Avg Vol 952,852
Day's Range N/A - N/A
Shares Out 46.05M
Stochastic %K 20%
Beta 1.47
Analysts Strong Sell
Price Target $96.75

Company Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical t...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 394 5230
Address:
Building 17, Suite 102b 221 Crescent Street, Waltham, United States
BallKnowerR
BallKnowerR Jul. 11 at 3:42 PM
$APGE This is too low at the moment. Building a healthy starter position. Lots of runway here, will keep adding over the coming weeks.
0 · Reply
amda
amda Jul. 11 at 3:39 PM
$APGE CEM97 - you ok, little buddy? this is green with the market down 300....I'm worried about you and those puts..
0 · Reply
amda
amda Jul. 11 at 2:45 PM
$APGE lol. CEM97 working hard this morning.
1 · Reply
CEM97
CEM97 Jul. 11 at 2:42 PM
$APGE easy puts or short buy
0 · Reply
amda
amda Jul. 11 at 2:41 PM
$APGE sniffed $40 yesterday. buying the dip under $38 for an afternoon surge....
0 · Reply
CEM97
CEM97 Jul. 11 at 2:38 PM
$APGE this is a dud. Come to $NKTR
0 · Reply
CEM97
CEM97 Jul. 11 at 2:08 PM
$APGE only have eyes for $NKTR nowadays
0 · Reply
CEM97
CEM97 Jul. 11 at 2:07 PM
$APGE dead
0 · Reply
Hailight
Hailight Jul. 11 at 10:36 AM
$APGE https://www.sharedeals.de/apogee-therapeutics-und-der-50-milliarden-dollar-markt/
0 · Reply
Eddie2023
Eddie2023 Jul. 10 at 11:24 PM
$APGE
0 · Reply
Latest News on APGE
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis

Jul 8, 2025, 4:50 PM EDT - 3 days ago

Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Jul 7, 2025, 6:00 AM EDT - 5 days ago

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Jul 6, 2025, 6:00 PM EDT - 5 days ago

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 29, 2025, 7:30 AM EDT - 6 weeks ago

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class

May 12, 2025, 4:04 PM EDT - 2 months ago

Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

May 12, 2025, 6:05 AM EDT - 2 months ago

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

May 12, 2025, 6:00 AM EDT - 2 months ago

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

May 1, 2025, 8:00 AM EDT - 2 months ago

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

Apogee Therapeutics: Engineering Biologic Dominance

Apr 14, 2025, 8:04 AM EDT - 3 months ago

Apogee Therapeutics: Engineering Biologic Dominance

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

Mar 3, 2025, 12:16 PM EST - 4 months ago

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Mar 3, 2025, 6:05 AM EST - 4 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Mar 3, 2025, 6:00 AM EST - 4 months ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Feb 28, 2025, 4:00 PM EST - 4 months ago

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Feb 25, 2025, 7:30 AM EST - 4 months ago

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Feb 3, 2025, 7:00 AM EST - 5 months ago

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 7:30 AM EST - 5 months ago

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Dec 2, 2024, 6:00 AM EST - 7 months ago

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Nov 29, 2024, 1:00 PM EST - 8 months ago

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Nov 18, 2024, 7:30 AM EST - 8 months ago

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Nov 10, 2024, 9:55 AM EST - 8 months ago

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

Nov 4, 2024, 7:30 AM EST - 8 months ago

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

Oct 16, 2024, 7:00 AM EDT - 9 months ago

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

Sep 12, 2024, 7:00 AM EDT - 10 months ago

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

Sep 9, 2024, 7:00 AM EDT - 10 months ago

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Aug 19, 2024, 7:00 AM EDT - 11 months ago

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 6:30 AM EDT - 11 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

Jun 18, 2024, 10:05 AM EDT - 1 year ago

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

May 28, 2024, 7:30 AM EDT - 1 year ago

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

May 23, 2024, 7:30 AM EDT - 1 year ago

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

May 15, 2024, 4:01 PM EDT - 1 year ago

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

May 6, 2024, 8:00 AM EDT - 1 year ago

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million

Mar 12, 2024, 4:01 PM EDT - 1 year ago

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

Mar 7, 2024, 6:49 PM EST - 1 year ago

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

Apogee Therapeutics: Success In Phase 1 Bodes Well For Continued APG777 Advancement

Mar 6, 2024, 4:13 PM EST - 1 year ago

Apogee Therapeutics: Success In Phase 1 Bodes Well For Continued APG777 Advancement

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Mar 5, 2024, 4:23 PM EST - 1 year ago

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management

Mar 5, 2024, 1:28 PM EST - 1 year ago

Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 5, 2024, 6:10 AM EST - 1 year ago

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sc

Mar 5, 2024, 6:00 AM EST - 1 year ago

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sc

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

Mar 4, 2024, 4:01 PM EST - 1 year ago

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 7:30 AM EST - 1 year ago

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 7:30 AM EST - 1 year ago

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

Sep 27, 2023, 8:42 AM EDT - 1 year ago

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day

Sep 14, 2023, 7:30 AM EDT - 1 year ago

Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day

Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results

Aug 28, 2023, 7:30 AM EDT - 2 years ago

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results

Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing

Aug 22, 2023, 8:14 AM EDT - 2 years ago

Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing

Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board

Aug 21, 2023, 7:30 AM EDT - 2 years ago

Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board

Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Aug 7, 2023, 7:30 AM EDT - 2 years ago

Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

BallKnowerR
BallKnowerR Jul. 11 at 3:42 PM
$APGE This is too low at the moment. Building a healthy starter position. Lots of runway here, will keep adding over the coming weeks.
0 · Reply
amda
amda Jul. 11 at 3:39 PM
$APGE CEM97 - you ok, little buddy? this is green with the market down 300....I'm worried about you and those puts..
0 · Reply
amda
amda Jul. 11 at 2:45 PM
$APGE lol. CEM97 working hard this morning.
1 · Reply
CEM97
CEM97 Jul. 11 at 2:42 PM
$APGE easy puts or short buy
0 · Reply
amda
amda Jul. 11 at 2:41 PM
$APGE sniffed $40 yesterday. buying the dip under $38 for an afternoon surge....
0 · Reply
CEM97
CEM97 Jul. 11 at 2:38 PM
$APGE this is a dud. Come to $NKTR
0 · Reply
CEM97
CEM97 Jul. 11 at 2:08 PM
$APGE only have eyes for $NKTR nowadays
0 · Reply
CEM97
CEM97 Jul. 11 at 2:07 PM
$APGE dead
0 · Reply
Hailight
Hailight Jul. 11 at 10:36 AM
$APGE https://www.sharedeals.de/apogee-therapeutics-und-der-50-milliarden-dollar-markt/
0 · Reply
Eddie2023
Eddie2023 Jul. 10 at 11:24 PM
$APGE
0 · Reply
StockHunter75
StockHunter75 Jul. 10 at 9:12 PM
$APGE bullish, good time to buy.
0 · Reply
CEM97
CEM97 Jul. 10 at 7:25 PM
$APGE loaded puts here heavy
1 · Reply
wallstreet63
wallstreet63 Jul. 10 at 7:25 PM
0 · Reply
wallstreet63
wallstreet63 Jul. 10 at 7:24 PM
$APGE over sold on great news and we're closer to the end result
0 · Reply
Project_Profit
Project_Profit Jul. 10 at 7:18 PM
$APGE
0 · Reply
CEM97
CEM97 Jul. 10 at 7:03 PM
$APGE wow…
0 · Reply
Pika_Capital
Pika_Capital Jul. 10 at 6:49 PM
$APGE accumulated whatever I wanted under $40. There is nothing in the middle here, you are either looking for 10x in 5 years or bust. R/r is very good since TAM is massive.
1 · Reply
Deekay1
Deekay1 Jul. 10 at 3:14 PM
$APGE Seems to be same action day after day...Pop a bit and give it all up by the end of the day...
0 · Reply
amda
amda Jul. 10 at 2:21 PM
$APGE The Dark Forces are certainly having their way with this one...when they decide to move it, we'll blast higher.
1 · Reply
idk_idk
idk_idk Jul. 10 at 2:06 PM
$APGE who cares about short time price action 🤗
0 · Reply
amda
amda Jul. 10 at 1:33 PM
$APGE squeeze shorty's nuts into raisins.....
0 · Reply
amda
amda Jul. 10 at 1:19 PM
$APGE 3 day rule should apply in full today. I'm looking for a big rebound. This is a green light situation - all news is very good.
0 · Reply